Navigation Links
Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010

PORTOLA VALLEY, Calif., May 11 /PRNewswire/ -- Spectros, developer and manufacturer of advanced molecular sensing and imaging devices which shed light on life-threatening diseases, presented 4 papers at the annual PAS conference held in Vancouver, B.C. May 1-4, 2010. The presented papers confirm the value added when using the T-Stat VLS tissue oximeter in neonates and infants for the detection of ischemia. The noninvasive white LED sensors provide a gentle way of monitoring, which is sensitive to this very delicate patient population.

"The abstracts and posters presented at PAS show a level of commitment from leading institutions and their support of the T-Stat in the critical care setting," comments Robert Kum, Director of Commercial Development. "Medical professionals depend on the T-Stat VLS Tissue Oximeter to get a clear view of tissue saturation, which enables them to make timely, more informed patient care decisions."

Duke University in Durham, NC put together a study on red blood cell transfusions and mesenteric perfusion in preterm infants.  The Pediatrics and Neonatology department at Georgetown University Hospital in Washington, DC presented the validation of visible light tissue oximetry in newborn infants. Noninvasive measurement of local tissue perfusion and its correlation with hemodynamic indices during transition in term infants was completed by The Children's Hospital at OU Medical Center in Oklahoma City, OK and postoperative differences in regional tissue oxygenation and fractional oxygen extraction (FTOE) in newborn infants with hypoplastic left heart syndrome (HLHS) and transposition of great arteries (TGA) was conducted at Columbia University in New York, NY.

"These studies have helped to define normal tissue oxygen extraction in newborn infants, for term, pre-term and congenital heart defect patients (hypoplastic left heart syndrome and transposition of the great arteries)," said Michael Fierro, Director of Research and Development. "These studies form the foundation for the work that Spectros and clinicians are currently exploring to define the clinical benefit of having an absolute, accurate, and reliable measure of tissue oxygen saturation in the newborn patient population."

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology. The noninvasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, allowing for earlier diagnosis and lower costs. Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns.  Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only.  T-Stat and Continuum are trademarks of the Spectros Corporation.)

For further information, visit

SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
2. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
3. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
4. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
5. County of Los Angeles Fire Museum Presents Pioneers of Paramedicine(TM) Lifetime Achievement Award
6. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
7. Celator(R) Pharmaceuticals Presents New Data on Two Nano-Scale Delivery Platforms at the American Association for Cancer Research
8. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
9. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
10. Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
11. Limbs for Life Foundation Presents the Roaring 20s at 9th Annual Benefit Gala and Auction
Post Your Comments:
(Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the ... capability and technology platform company serving the pharmaceutical, biotechnology, ... China and the United States ... meeting of shareholders held today, the Company,s shareholders voted ... the previously announced agreement and plan of merger (the ...
(Date:11/24/2015)... , Nov. 24, 2015  In the pharmaceutical ... in an effort to quickly uncover new insights, tactics ... --> --> However, organizations ... market research project and ensure that all rules and ... industry standards. Another major barrier to efficiently launching market ...
(Date:11/24/2015)... Nov. 24, 2015  DILON Diagnostics and GE Healthcare ... agreement for DILON to distribute GE,s Discovery NM750b Molecular ... signing of this distribution agreement will provide Dilon,s experienced ... Imaging system and is considered an initial step in ... solutions for clinicians and their patients. ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... ... , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, ... FDA has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls ... meet the device regulations. , Come up short in an inspection and the FDA ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... In response ... growing epidemic as deaths from prescription opioids in the United States grew 400 percent ... In 2013 alone, opioids were involved in 37 percent of all fatal drug overdoses. ...
(Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
Breaking Medicine News(10 mins):